Literature scope
Janvier et al. 2018 is listed on this page. The direct answer also uses the European Medicines Agency 2025 guideline and the University of Calgary 2026 bulletin, which are filed source pages. Some sections below are still empty because they have not been filled.
Direct answer
For the question of whether research peptides get heavy-metal tested, this category page does not name vendors. Janvier et al. 2018 acquired 27 unregulated polypeptide preparations sold as research chemicals, measured elemental impurities by ICP-MS against ICH Q3D parenteral limits, and reported inorganic arsenic at 1660 to 12,890 ppb in 6 of 27 preparations against a cited arsenic limit of 1500 ppb, with one of 27 above a cited lead limit of 500 ppb and no printed lead concentration for that sample, while mercury and nickel had insufficient material to assess (Impurity profiling of the most frequently encountered falsified polypeptide drugs on the Belgian market, DOI 10.1016/j.talanta.2018.06.023). The European Medicines Agency 2025 guideline places authorized synthetic peptide medicines under ICH Q3D and prints no occurrence concentration (Guideline on the Development and Manufacture of Synthetic Peptides, no DOI), and the University of Calgary 2026 bulletin prints no original measurement (Clinical Pharmacology & Toxicology Pearl of the Week — Unauthorized Injectable Peptides, no DOI).
References
Works cited in this page’s text, in first-appearance order. This is not the full corpus for this page; it is only what the prose above draws on. The complete set of sources is listed under Sources below. Each title links to its source record.
Sources
Sources catalogued for this page. The last column says how each source is used here.
| # | Citation | Year | Type | Used on this page for |
|---|---|---|---|---|
| 1 | Craven et al. 2025. Lead Astray? The Hidden Contaminants in Australian Anabolic–Androgenic Steroid Market and Their Potential Health Impact, Drug and Alcohol Review | 2025 | Peer-reviewed | AU Pb, Cd, tAs, Al, Cr, Ni occurrence in 28 illicit anabolic–androgenic steroid (AAS) products anonymously donated by people who use AAS in Australia (reportedly purchased 2022–2024):… (n=28) |
| 2 | Janvier et al. 2018. Impurity profiling of the most frequently encountered falsified polypeptide drugs on the Belgian market, Talanta | 2018 | Peer-reviewed | BE iAs, tAs, Pb, Cd occurrence in 27 falsified/unregulated polypeptide drug preparations acquired as ‘research chemicals’ from three suspected illegal internet pharmacies and delivered to… (n=27) |
| 3 | University of Calgary Clinical 2026. Clinical Pharmacology & Toxicology Pearl of the Week — Unauthorized Injectable Peptides, CPT Pearl of the Week (Alberta Health Services / University of Calgary Cumming School of Medicine) | 2026 | Government report | Contribution to this topic remains under review; see the source record for its reported scope. |
| 4 | EMA 2025. Guideline on the Development and Manufacture of Synthetic Peptides, European Medicines Agency | 2025 | Regulatory guideline | Contribution to this topic remains under review; see the source record for its reported scope. |
Update history
The five most recent substantive edits to this page, classified major (evidence or structure moved), correction (a published value or statement was wrong and has been fixed), or minor (narrative rewritten without changing the underlying evidence). Each description is derived from what the edit did to this page; the linked commit is the authoritative record, routine regeneration passes are excluded, and the full version history lives in git. When DOI minting comes online (see schema docs), each entry below will also link to a version-pinned DataCite DOI.
| Commit | Date | Change | Description |
|---|---|---|---|
| b01ec52c3 | 2026-08-04 | major | 1 source added; narrative text revised |
| 3a67e1307 | 2026-08-02 | minor | Narrative text revised |
| 33273ad69 | 2026-08-02 | major | 1 source added; narrative text revised |
| 90a2f9a38 | 2026-07-30 | major | 2 sections added and 1 removed; narrative text revised |
| bff8abb72 | 2026-07-27 | correction | 2 sections added and 1 removed; narrative text revised |